TransCode Therapeutics Reports Sustained Disease Control in Early Cancer Trial

TransCode Therapeutics announced updated clinical data from its Phase 1a trial of TTX-MC138 for advanced solid tumors. The investigational anti-miR-10b therapeutic candidate showed a 71.4% stable disease rate among evaluable patients, with some maintaining disease control for up to one year. These results suggest durable antitumor activity, providing encouraging early signals for patients with relapsed or refractory cancers.